Primer sequences for polymerase chain reactions.

<p>Primer sequences for polymerase chain reactions.</p

Proportion of G6PD enzyme activity levels for male and female participants compared to adjusted male median value.

<p>For each G6PD enzyme activity level (U/g Hb) shown in X-axis, the corresponding value in Y-axis indicates the number of participants. The numbers on top of each dotted line, shown as 10, 20, 30, and 60 on uppermost horizontal line of the graph indicate different cut-off values as percentages for the study population. 60% (shown as 60) of adjusted male median (shown as 100) is the upper limit of cut-off value and the participants with enzyme activities below 60% are considered deficient. Black portion of each bar indicates male participants, whereas gray portion of each bar indicates female participants.</p

Distribution of demographic information between non-deficient and deficient participants.

<p>Distribution of demographic information between non-deficient and deficient participants.</p

Hemoglobin levels and reticulocyte counts in G6PD non-deficient (ND) and deficient (D) participants.

<p>(A) Depicts hemoglobin levels (g/dL), and (B) Demonstrates reticulocyte counts (%) in non-deficient and deficient participants. A p-value < 0.05 was considered statistically significant.</p

Fluorescent spot test and enzyme assay results of deficient samples along with reticulocytes counts.

<p>Fluorescent spot test and enzyme assay results of deficient samples along with reticulocytes counts.</p

Reference values to describe the G6PD activity profile for study population.

<p>Reference values to describe the G6PD activity profile for study population.</p

Survival likelihood of neonatal CD-1 mice following oral challenge with wild-type O1 Ogawa <i>V. cholerae</i> O395.

<p>Three- to five-day-old pups (cohort size 20) were orally gavaged with 50 µl of a preparation containing 2.3×10⁹ CFU of wild type <i>V. cholerae</i> O395 mixed with a 1∶250 dilution of pooled day 56 serum from mice intramuscularly immunized with conjugate vaccine (OSP:TThc) and immunoadjuvantative dmLT, or dmLT alone. Survival curves were compared by log rank testing.</p

Immunoreactivity in human plasma of OSP:rTTHc, OSP:BSA, and TT.

<p>Immunoreactivity of OSP:rTTHc, OSP:BSA and TT was measured in day 2 versus day 7 plasma of patients with cholera versus typhoid fever in Dhaka, Bangladesh.</p

Vibriocidal responses in mice intramuscularly immunized with OSP:TThc (with dmLT), OSP (with dmLT), OSP:TThc (no dmLT), OSP (no dmLT), or dmLT alone.

<p>The columns indicate mean reciprocal end titers, and error bars represent the standard errors of the mean. An asterisk denotes a statistically significant difference (<i>P</i><0.05) from baseline (day 0) titer. Responder frequencies are also listed. #, statistically significant difference among the vaccine cohorts (<i>P</i><0.05).</p

Memory B cell IgG responses in spleen at day 56 targeting O-specific polysaccharide (OSP) in various vaccine cohorts following intramuscular (IM) or intradermal (ID) immunization with various doses (based on OSP component) and/or loading ratios of OSP to TTHc, with or without adjuvantative alum.

<p>Mice were immunized on days 0, 21, and 42. Responder frequency reflects an increase of >5 times total IgG secreting cells with stimulation versus no stimulation, and >3.5 anti-OSP spots per 10⁵ splenocytes. An asterisk denotes a statistically significant difference (<i>P</i><0.05) in the mean response from the group immunized with only alum.</p